secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001193125-26-039475
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences raises ~$87.1M in ATM offering; 2.25M shares sold at $38.76 VWAP
--------------------------------------------------------------------------------

- Closed sale of 2,250,986 shares at a volume-weighted average price of $38.76 for gross proceeds of approximately $87.1 million on February 4, 2026.
- Shares sold under Open Market Sale Agreement with Jefferies dated November 6, 2025, and shelf registration statement effective December 8, 2025.
- Net proceeds to fund clinical-stage programs, discovery R&D, working capital, and potential in-licensing or acquisitions.
- Following this sale, up to $62.9 million in additional common stock remains available for future ATM sales through Jefferies.
- Company retains flexibility to use proceeds for general corporate purposes and complementary business investments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526039475/0001193125-26-039475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526039475/mbx-20260204.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-039475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer